- Home
- DEO vs BDX Comparison
DEO vs BDX Comparison
Compare DEO & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEO | BDX |
|---|---|---|
| Founded | 1886 | 1897 |
| Country | United Kingdom | United States |
| Employees | 29860 | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 51.5B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | DEO | BDX |
|---|---|---|
| Price | $81.81 | $143.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $109.00 | ★ $186.00 |
| AVG Volume (30 Days) | 1.4M | ★ 3.0M |
| Earning Date | 02-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.18% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $2.65 | N/A |
| Revenue Next Year | N/A | $3.02 |
| P/E Ratio | ★ $90.04 | $577.32 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $72.45 | $142.83 |
| 52 Week High | $116.41 | $213.08 |
Technical Indicators
Market Signals| Indicator | DEO | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 38.94 |
| Support Level | $72.73 | N/A |
| Resistance Level | $82.78 | $158.66 |
| Average True Range (ATR) | 1.43 | 4.35 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 56.33 | 7.96 |
Price Performance
Historical ComparisonAbout DEO Diageo plc
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.
About BDX Becton Dickinson and Company
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.